AMAG AMAG Pharmaceuticals Inc.

-0.08  -1%
Previous Close 11.91
Open 11.83
Price To Book 0.55
Market Cap 399224975
Shares 33,746,828
Volume 818,340
Short Ratio
Av. Daily Volume 751,612

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 enrolment to be completed YE 2019.
Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
PDUFA date extended to June 23, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Approval for sNDA filing announced February 5, 2018.
Adults with iron deficiency anemia (IDA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
Phase 3b trial did not meet co-primary endpoints - March 8, 2019.
Preterm birth

Latest News

  1. AMAG Pharmaceuticals Appoints Nancy Griffith, PH.D., as Vice President of Scientific Communications and Medical Operations
  2. The AMAG Pharmaceuticals (NASDAQ:AMAG) Share Price Is Down 51% So Some Shareholders Are Wishing They Sold
  3. AMAG Pharmaceuticals Appoints New Members to Board of Directors
  4. AMAG Pharmaceuticals to Present at Needham 18th Annual Healthcare Conference
  5. March of Dimes and AMAG Pharmaceuticals, Inc., Announce First Joint Supportive Pregnancy Care Program
  6. New Doubt on Treatment to Prevent Preterm Birth
  7. Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
  8. AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
  9. Why Is AMAG Pharmaceuticals (AMAG) Down 24.5% Since Last Earnings Report?
  10. Amag's shares fall after $323M pregnancy drug fails in post-approval trial
  11. AMAG Pharmaceuticals stock down 6% after latest trial of Makena fails to meet primary endpoints
  12. AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena® (hydroxyprogesterone caproate injection)
  13. AMAG Pharmaceuticals Presents New Data on Bremelanotide and Hypoactive Sexual Desire Disorder at the ISSWSH/ISSM Joint Meeting
  14. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
  15. AMAG Pharmaceuticals Inc (AMAG) Files 10-K for the Fiscal Year Ended on December 31, 2018
  16. Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
  17. AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference
  18. Edited Transcript of AMAG earnings conference call or presentation 7-Feb-19 1:00pm GMT
  19. AMAG Pharmaceuticals (AMAG) Q4 2018 Earnings Conference Call Transcript
  20. AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates